James Blome is the President & CEO for Bayer CropScience, LP and the Head of Crop Protection for the North American region.  Jim brings more than 30 years of leadership experience in agriculture and is located in the Crop Science division’s North American headquarters in Research Triangle Park, NC.

Outside of Bayer, Jim serves as Founding Chairman of the Board for US Farming and Ranching Foundation, the Chairman of Inocucor (USA and Canada) and the Vice-Chair of CropLife America.

Jim grew up on a family corn and soybean farm in Hubbard, Iowa and is a degreed agronomist from Iowa State University. He is the 2013 recipient of the Henry A. Wallace Award from Iowa State University for outstanding leadership and service to agriculture.




Mr. Marvin has been a biotechnology entrepreneur and leader in the commercialization of new life sciences diagnostic and research technologies and products for more than 30 years.

Prior to joining Inocucor® Technologies, he was the president and CEO of Cairn Associates Inc., a biotechnology, life science and consumer products strategy development and financial advisory firm.

Most recently, Mr. Marvin was the president and CEO of IdentiGEN, Inc., a leading provider of DNA-based solutions to the agriculture and food industries. He was a co-founder of Nasdaq-traded Orchid BioSciences, a pioneer in human DNA identity testing, where he served as its chief operating officer, chief financial officer and senior vice president of corporate development.

Previously, Mr. Marvin was president and CEO of Diatron Corporation, a biomedical company developing fluorescence-based instrument systems for the clinical diagnostics industry.

His expertise includes strategic planning, business development, technical administration and operations at PepsiCo, Abbott Laboratories and Bayer AG, as well as domestic and international marketing and sales for the clinical diagnostics subsidiary of Boehringer Ingelheim.

Mr. Marvin is a serial entrepreneur with a track record of building exceptional value for stakeholders at several life science and agri-food companies. Formerly New Jersey’s CFO of the year, he has raised over $350 million in both private and public financings and completed nearly a dozen M&A transactions for his former companies. Mr. Marvin has served on the boards of several public and privately held companies and currently serves on the board of MicroBiome Therapeutics, Inc.

He earned a B.S. in microbiology from Ohio State University and an M.B.A. in organizational behavior and finance from Iona College.



Managing Partner, Cycle Capital Management

Mr. Vachet has 22 years of operational, venture capital, secondary transaction and fund management experience of venture capital portfolios investing in high tech companies.

Having managed numerous investments and exits during his career, Mr. Vachet has built a solid track record. He has, among others, been part of successful teams at both Kirchner and Multiple Capital.

He also worked at Innovatech Montreal as Vice-President Information Technology and Communication. In this capacity, he was responsible for 44 high-tech start-up companies and five venture capital funds. From April 2004 to March 2005, he participated in the sale of Innovatech Montreal’s portfolio, the second largest transaction in a venture capital portfolio in Canada with its 108 companies and 15 funds.

Mr. Vachet has broad corporate governance experience at board level as well as on audit, HR, strategic and M&A committees. He has occupied numerous board functions and duties as a director and chairperson on more than 30 company boards over the past 15 years.

Early in his career, Mr. Vachet acquired operational experience in the commercialization of cleantech technologies (water, energy, waste and other industrial applications) in a large multinational corporation across North America and China (Lyonnaise des eaux – Degrémont).

Mr. Vachet holds a Chemical Engineering degree from École Polytechnique (Montreal) and an M.B.A. in Finance from HEC-Montreal.




Prior to joining TPG in 2004, Dr. Geoff Duyk served on the board of directors and was President of Research & Development at Exelixis, Inc., where he led a group of more than 550 people focused on the discovery and development of small molecule therapeutics.

Prior to Exelixis, Inc., he was one of the founding scientific staff at Millennium Pharmaceuticals, Inc. As Vice President of Genomics at Millennium Pharmaceuticals, Inc., Dr. Duyk was responsible for building and leading the informatics, automation, DNA sequencing and genotyping groups as well as the mouse and human genetics group.

Prior to this, Dr. Duyk was an Assistant Professor at Harvard Medical School in the Department of Genetics and Assistant Investigator of the Howard Hughes Medical Institute. While at Harvard Medical School, he was a Co-Principal Investigator in the NIH-funded Cooperative Human Linkage Center.

Dr. Duyk has been and continues to be a member of numerous NIH panels and oversight committees focused on the planning and execution of the Human Genome Project, and is the Treasurer and a Director of the American Society of Human Genetics.

He graduated from Wesleyan University in 1980 with a B.A. in Biology and was elected to Phi Beta Kappa. He holds a Ph.D. and M.D. from Case Western Reserve University and completed his medical and fellowship training at UCSF. While at UCSF, he was a fellow of the Lucille P. Markey Foundation and was also awarded a post-doctoral fellowship from the Howard Hughes Medical Institute.

Dr. Duyk is a former trustee of Wesleyan University and is a trustee of Case Western Reserve University. He is a Fellow of the American Association for the Advancement of Science. In addition to Inocucor, he currently serves on the boards of directors of: Amyris, Inc.; Beta Renewables; DNAnexus, Inc.; Elevance Renewable Sciences; and ReGen Holdings Limited.